Patient selection in sham-controlled trials of antireflux mucosal ablation: who benefits and why?
Endoscopy · 01.09.2026 · 58 (09) · 1067
DOI: 10.1055/a-2890-0493 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.09.2026. Verfasst von Varan Perananthan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Rochester, Division of Gastroenterology and Hepatology, Minnesota, United States, Rochester.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Mayo Clinic, Rochester, Division of Gastroenterology and Hepatology, Minnesota, United States, Rochester.
- IRCCS San Raffaele Hospital, Gastroenterology and Gastrointestinal Endoscopy Unit, Italy, Milan.
ORCID-Profile: Varan Perananthan, Francesco Vito Mandarino
Zitieren
APA
Perananthan, V., & Mandarino, F. V. (2026). Patient selection in sham-controlled trials of antireflux mucosal ablation: who benefits and why?. Endoscopy, 58(09), 1067. https://doi.org/10.1055/a-2890-0493
Vancouver
Perananthan V, Mandarino FV. Patient selection in sham-controlled trials of antireflux mucosal ablation: who benefits and why?. Endoscopy. 2026;58(09):1067. doi:10.1055/a-2890-0493
BibTeX
@article{Perananthan2026,
author = {Perananthan, Varan and Mandarino, Francesco Vito},
title = {Patient selection in sham-controlled trials of antireflux mucosal ablation: who benefits and why?},
journal = {Endoscopy},
year = {2026},
volume = {58},
number = {09},
pages = {1067},
doi = {10.1055/a-2890-0493}
}
EUVIMED